scholarly journals A New Solid-Phase Immunosorbent for Selective Binding of Desmoglein 3 Autoantibodies in Patients with Pemphigus Vulgaris

Acta Naturae ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 63-69
Author(s):  
T. V. Abramova ◽  
M. V. Spilevaya ◽  
A. A. Kubanov
Keyword(s):  
Side Effects ◽  
Adjuvant Therapy ◽  
Solid Phase ◽  
Pemphigus Vulgaris ◽  
Risk Of Infection ◽  
Systemic Corticosteroids ◽  
Pemphigus Antibodies ◽  
Affinity Sorbent ◽  
Extracorporeal Therapy ◽  
Desmoglein 3

Autoantibodies, immunoglobulins G (IgG) againstthe desmosomal proteins desmogleins 1 and 3, play a significant role in the pathogenesis of pemphigus vulgaris. The basic therapy for pemfigus includes systemic corticosteroids, but their use should be as briefas possible because of the severe side effects. In cases of corticosteroid-resistant pemfigus, adjuvant therapy, in particularextracorporeal methods, is used. The most effective and safest extracorporeal therapy is immunosorbtion. Immunosorbtion is based on the removal of pemphigus antibodies from the blood using an affinity sorbent during a therapeutic apheresis procedure. Existing immunosorbents are nonselective and increase the risk of infection. We designed an immunosorbent based on an agarose matrix, Affi-Gel 15, and human recombinant desmoglein 3, as aligand, for a selective removal of autoantibodies from pemphigus patients sera. It was shown on a pemphigus experimental modelin vivo(neonatal Balb/c mouse model) andin vitrothat the immunosorbent can effectively remove desmoglein 3-associated autoantibodies. The experimental results demonstrate that the solid-phase matrix immunosorbent Affi-Gel 15Dsg3 is a promising product for the development of pemphigus therapy.

scholarly journals Adjuvant Radiotherapy after Surgical Excision in Keloids

Medicina ◽  
2021 ◽  
Vol 57 (7) ◽  
pp. 730
Author(s):  
Jeong Won Lee ◽  
Ki Ho Seol
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Adjuvant Therapy ◽  
Local Control ◽  
Adjuvant Radiotherapy ◽  
Surgical Excision ◽  
Recurrence Rates ◽  
High Tendency ◽  
Advantages And Disadvantages

Keloids are a benign fibroproliferative disease with a high tendency of recurrence. Keloids cause functional impairment, disfigurement, pruritus, and low quality of life. Many therapeutic options have been used for keloids. However, the high recurrence rates have led to the use of adjuvant therapy after surgical keloid excision. There are different radiotherapy regimens available, and the advantages and disadvantages of each are still unclear. The aim of this review is to explain the appropriate radiotherapy regimen for keloids as well as discuss the recent reports on keloid management with radiotherapy. Adjuvant radiotherapy after surgical excision for keloids yields excellent local control with tolerable side effects. Hypofractionated radiotherapy with a BED of more than 28 Gy (α/β value of 10) after excision is recommended in the light of its biologic background.

Binding of pemphigus antibodies to the epidermis of mice lacking desmoglein 3

1998 ◽  
Vol 16 ◽  
pp. S35
Author(s):  
Vu Thuong Nguyen ◽  
Assane Ndoye ◽  
Leonard D. Shultz ◽  
Sergei A. Grando
Keyword(s):  
Pemphigus Antibodies ◽  
Desmoglein 3

scholarly journals Serum Levels of Autoantibodies to Desmoglein 3 in Patients with Therapy-resistant Pemphigus Vulgaris Successfully Treated with Adjuvant Intravenous Immunoglobulins

2003 ◽  
Vol 84 (1) ◽  
pp. 48-52
Author(s):  
Detlef Zillikens ◽  
Susanne Herzog ◽  
Enno Schmidt ◽  
Matthias Goebeler ◽  
Bröcker Eva-B.
Keyword(s):  
Pemphigus Vulgaris ◽  
Serum Levels ◽  
Intravenous Immunoglobulins ◽  
Desmoglein 3

scholarly journals Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice

2018 ◽  
Vol 9 ◽  
Author(s):  
Maxi Hofrichter ◽  
Jenny Dworschak ◽  
Shirin Emtenani ◽  
Jana Langenhan ◽  
Fanny Weiß ◽  
...  
Keyword(s):  
Pemphigus Vulgaris ◽  
Neonatal Mice ◽  
Specific Igg ◽  
Desmoglein 3

scholarly journals Citrobacter freundii sepsis in an immunosuppressed patient with pemphigus vulgaris

2018 ◽  
Vol 11 (1) ◽  
pp. e227091 ◽  
Author(s):  
Martina Ferranti ◽  
Giulia Tadiotto Cicogna ◽  
Andrea Sattin ◽  
Mauro Alaibac
Keyword(s):  
Immunosuppressive Agents ◽  
Pemphigus Vulgaris ◽  
Immunosuppressed Patient ◽  
Citrobacter Freundii ◽  
Bullous Disease ◽  
Autoimmune Bullous Disease ◽  
Systemic Corticosteroids ◽  
Mucous Membranes ◽  
Current Therapies ◽  
Anti Cd20

Pemphigus vulgaris is an autoimmune bullous disease that involves the skin and mucous membranes. Current therapies aim to decrease antibody production by means of the use of systemic corticosteroids, immunosuppressive agents and, recently, rituximab, an anti-CD20 monoclonal antibody. However, the chronic immune suppression could entail complications, like infections and secondary malignancies. We describe a case of a patient with pemphigus who developed a sepsis due to Citrobacter freundii infection.

Transgenic rescue of desmoglein 3 null mice with desmoglein 1 to develop a syngeneic mouse model for pemphigus vulgaris

2011 ◽  
Vol 63 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Tsuyoshi Hata ◽  
Koji Nishifuji ◽  
Kouji Shimoda ◽  
Takashi Sasaki ◽  
Taketo Yamada ◽  
...  
Keyword(s):  
Mouse Model ◽  
Pemphigus Vulgaris ◽  
Syngeneic Mouse ◽  
Syngeneic Mouse Model ◽  
Desmoglein 3
Sign in / Sign up

Export Citation Format

Share Document